Clinical Evidence
16 articles tagged “Clinical Evidence”
Learn
Genetic Study Links Higher Testosterone to 17% Heart Risk
A Cambridge Mendelian randomization study of 1.4 million people found genetically higher testosterone raises coronary artery disease risk 17% in men.
Testosterone Gel Cuts Visceral Fat in Women After Hip Fracture
The STEP-HI trial found testosterone gel plus exercise reduced dangerous visceral belly fat by 10.6% in older women recovering from hip fractures.
TRT Cuts Death Risk 22% in Kidney Disease Patients
A 2026 propensity-matched study of 3,090 men with CKD found TRT lowered mortality 22% with no rise in heart attacks, strokes, or prostate cancer.
Aviva AVA-291: Aromatization-Resistant Testosterone for Women
Aviva Bio's AVA-291 is a deuterium-modified testosterone designed to resist aromatization and lower breast-cancer-cell-proliferation signal by approximately 1,000-fold.
TRT Before Hip and Shoulder Surgery: New 2026 Data
Two propensity-matched 2026 studies show preoperative TRT raises infection, kidney injury, and revision rates after hip and shoulder replacement.
TRT After Prostate Cancer: SPIRIT Trial Results
A new JAMA Internal Medicine trial randomized 136 prostate cancer survivors to testosterone or placebo. Here's what 24 weeks of data showed.
Testosterone Therapy CV Safety in Women: 2026 Review
Feb 2026 systematic review of 2,628 women on testosterone: zero cardiovascular deaths in trials. What the data actually says — and where the gaps are.
Acrux Advances Female Testosterone to Phase 3 for HSDD
On April 30, 2026, Acrux announced Phase 3 trials for a transdermal female testosterone product for HSDD. Here is what it means and what is available now.
Blood Test Flags Combined HRT Dementia Risk in Some
March 2026 JAMA study: high p-tau217 plus combined HRT linked to 4x dementia risk. What it means if you are on or considering hormone therapy.
European TRT Verdict: AFib Signal, Heart Safety
Europe's testosterone expert panel issued its 2026 TRAVERSE verdict. Heart attacks reassuring, atrial fibrillation signal real. What changes for you.
TRT, Heart Risk, and Prostate Cancer: 41-Trial Review
A new 2026 meta-analysis pooled 41 RCTs and 11,161 men. Here's what it actually says about TRT, heart attacks, strokes, and prostate cancer.
Low T Tied to Prostate Cancer Progression: 924 Men
A 2026 MD Anderson study found low testosterone raised the odds of high-grade prostate cancer progression on active surveillance by 61 percent.
Diabetes Triples Low T Risk: New NHANES Study
A 2026 NHANES analysis using gold-standard testosterone testing names diabetes, obesity, and isolation as the real drivers of low T in American men.
HRT + Tirzepatide: 35% More Menopause Weight Loss
Postmenopausal women on HRT lost 19.2% of body weight on tirzepatide vs 14% without. Mayo Clinic Lancet data, who it's for, the clinic angle.
9,537 Men on TRT: Real-World Safety Data
A new 2026 cohort tracked 9,537 men on TRT for up to a year. Here's what the data says about hematocrit, libido, and who runs into trouble.
